Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Updating of a method for causality assessment of adverse drug reactions.

International journal of clinical pharmacology, therapy, and toxicology

Venulet J, Ciucci AG, Berneker GC.
PMID: 3781677
Int J Clin Pharmacol Ther Toxicol. 1986 Oct;24(10):559-68.

The paper represents an update of a method of standardized assessment of causality that was published in 1980. Because of experience that was gained in the meantime, weighting of certain types of information was modified and several weighting tables...

Cite
Venulet J, Ciucci AG, Berneker GC. Updating of a method for causality assessment of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol. 1986;24(10):559-68
Venulet, J., Ciucci, A. G., & Berneker, G. C. (1986). Updating of a method for causality assessment of adverse drug reactions. International journal of clinical pharmacology, therapy, and toxicology, 24(10), 559-68.
Venulet, J, et al. "Updating of a method for causality assessment of adverse drug reactions." International journal of clinical pharmacology, therapy, and toxicology vol. 24,10 (1986): 559-68.
Venulet J, Ciucci AG, Berneker GC. Updating of a method for causality assessment of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol. 1986 Oct;24(10):559-68. PMID: 3781677.
Copy Download .nbib Format: NLM
Erratum.

International journal of clinical pharmacology and therapeutics

[No authors listed]
PMID: 26229998
Int J Clin Pharmacol Ther. 2015 May;53(5):414.

No abstract available.

Cite
Erratum. Int J Clin Pharmacol Ther. 2015;53(5):414
(2015). Erratum. International journal of clinical pharmacology and therapeutics, 53(5), 414.
"Erratum." International journal of clinical pharmacology and therapeutics vol. 53,5 (2015): 414.
Erratum. Int J Clin Pharmacol Ther. 2015 May;53(5):414. PMID: 26229998.
Copy Download .nbib Format: NLM
The responsibility for the study protocol in a drug trial.

International journal of clinical pharmacology, therapy, and toxicology

Schmidt R.
PMID: 3997301
Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):158-60.

A well-designed protocol is an essential part of any clinical trial. In a drug trial it should be the result of a joint effort involving the physician performing the trial at the clinic and the specialist in the drug...

Cite
Schmidt R. The responsibility for the study protocol in a drug trial. Int J Clin Pharmacol Ther Toxicol. 1985;23(3):158-60
Schmidt, R. (1985). The responsibility for the study protocol in a drug trial. International journal of clinical pharmacology, therapy, and toxicology, 23(3), 158-60.
Schmidt, R. "The responsibility for the study protocol in a drug trial." International journal of clinical pharmacology, therapy, and toxicology vol. 23,3 (1985): 158-60.
Schmidt R. The responsibility for the study protocol in a drug trial. Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):158-60. PMID: 3997301.
Copy Download .nbib Format: NLM
Necessity and requirements of bridging studies and their present status in Japan.

International journal of clinical pharmacology and therapeutics

Naito C.
PMID: 10706195
Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080.

The mainstays of the harmonized final document about ethnic factors in the acceptability of foreign clinical data include a complete clinical data package and a bridging study (for efficacy and/or for safety). A clinical data package that meets all...

Cite
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38(2):80-6doi: 10.5414/cpp38080.
Naito, C. (2000). Necessity and requirements of bridging studies and their present status in Japan. International journal of clinical pharmacology and therapeutics, 38(2), 80-6. https://doi.org/10.5414/cpp38080
Naito, C. "Necessity and requirements of bridging studies and their present status in Japan." International journal of clinical pharmacology and therapeutics vol. 38,2 (2000): 80-6. doi: https://doi.org/10.5414/cpp38080
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080. PMID: 10706195.
Copy Download .nbib Format: NLM
COVID 19: Pandemic assessment and management using Incidence.

International journal of clinical pharmacology and therapeutics

Braun P, Woodcock BG.
PMID: 34854373
Int J Clin Pharmacol Ther. 2021 Dec 02; doi: 10.5414/CPP60001. Epub 2021 Dec 02.

No abstract available.

Cite
Braun P, Woodcock BG. COVID 19: Pandemic assessment and management using Incidence. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CPP60001.
Braun, P., & Woodcock, B. G. (2021). COVID 19: Pandemic assessment and management using Incidence. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CPP60001
Braun, Peter, and Woodcock, Barry G. "COVID 19: Pandemic assessment and management using Incidence." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CPP60001
Braun P, Woodcock BG. COVID 19: Pandemic assessment and management using Incidence. Int J Clin Pharmacol Ther. 2021 Dec 02; doi: 10.5414/CPP60001. Epub 2021 Dec 02. PMID: 34854373.
Copy Download .nbib Format: NLM
Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.

International journal of clinical pharmacology and therapeutics

Lee YH, Song GG.
PMID: 34889733
Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204108. Epub 2021 Dec 10.

OBJECTIVE: We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout.MATERIALS AND METHODS: A Bayesian network meta-analysis was performed to combine direct and indirect evidence from randomized controlled...

Cite
Lee YH, Song GG. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204108.
Lee, Y. H., & Song, G. G. (2021). Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204108
Lee, Young Ho, and Song, Gwan Gyu. "Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204108
Lee YH, Song GG. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204108. Epub 2021 Dec 10. PMID: 34889733.
Copy Download .nbib Format: NLM
Drug-induced, mixed-type hepatitis following ingestion of .

International journal of clinical pharmacology and therapeutics

Thurian D, Montani M, Stickel F.
PMID: 34889735
Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204139. Epub 2021 Dec 10.

The use of herbal and dietary supplements is increasing worldwide. Consumers consider it as a natural, and therefore safe and healthy alternative to conventional synthetic drugs and do not expect adverse effects. However, numerous herbal and dietary supplements have...

Cite
Thurian D, Montani M, Stickel F. Drug-induced, mixed-type hepatitis following ingestion of . Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204139.
Thurian, D., Montani, M., & Stickel, F. (2021). Drug-induced, mixed-type hepatitis following ingestion of . International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204139
Thurian, Dario, et al. "Drug-induced, mixed-type hepatitis following ingestion of ." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204139
Thurian D, Montani M, Stickel F. Drug-induced, mixed-type hepatitis following ingestion of . Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204139. Epub 2021 Dec 10. PMID: 34889735.
Copy Download .nbib Format: NLM
Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life.

International journal of clinical pharmacology and therapeutics

Sanga M, Vaughan S, Nangosyah J, Scholz V, Fonseca S.
PMID: 34779392
Int J Clin Pharmacol Ther. 2021 Nov 15; doi: 10.5414/CP204034. Epub 2021 Nov 15.

OBJECTIVE: Evaluate bioequivalence, based on norelgestromin (NGMN) and ethinyl estradiol (EE) plasma concentrations, and adhesion of a transdermal contraceptive patch containing a newly sourced adhesive component (test) at end of shelf life (EOSL) vs. the marketed EVRA patch (reference)...

Cite
Sanga M, Vaughan S, Nangosyah J, et al. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204034.
Sanga, M., Vaughan, S., Nangosyah, J., Scholz, V., & Fonseca, S. (2021). Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204034
Sanga, Madhu, et al. "Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204034
Sanga M, Vaughan S, Nangosyah J, Scholz V, Fonseca S. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. Int J Clin Pharmacol Ther. 2021 Nov 15; doi: 10.5414/CP204034. Epub 2021 Nov 15. PMID: 34779392.
Copy Download .nbib Format: NLM
Off-label prescribing during pregnancy in France: the NéHaVi cohort
.

International journal of clinical pharmacology and therapeutics

Laroche ML, Blin A, Coubret A, Grau M, Roux B, Aubard Y.
PMID: 31933473
Int J Clin Pharmacol Ther. 2020 Apr;58(4):198-208. doi: 10.5414/CP203578.

OBJECTIVE: To describe the off-label medication use in a cohort of pregnant women.MATERIAL AND METHODS: We performed a multicenter prospective longitudinal observational study in the Haute-Vienne department (France) called the NéHaVi cohort ("Né en Haute-Vienne" meaning "born in Haute-Vienne")....

Cite
Laroche ML, Blin A, Coubret A, et al. Off-label prescribing during pregnancy in France: the NéHaVi cohort
. Int J Clin Pharmacol Ther. 2020;58(4):198-208doi: 10.5414/CP203578.
Laroche, M. L., Blin, A., Coubret, A., Grau, M., Roux, B., & Aubard, Y. (2020). Off-label prescribing during pregnancy in France: the NéHaVi cohort
. International journal of clinical pharmacology and therapeutics, 58(4), 198-208. https://doi.org/10.5414/CP203578
Laroche, Marie-Laure, et al. "Off-label prescribing during pregnancy in France: the NéHaVi cohort
." International journal of clinical pharmacology and therapeutics vol. 58,4 (2020): 198-208. doi: https://doi.org/10.5414/CP203578
Laroche ML, Blin A, Coubret A, Grau M, Roux B, Aubard Y. Off-label prescribing during pregnancy in France: the NéHaVi cohort
. Int J Clin Pharmacol Ther. 2020 Apr;58(4):198-208. doi: 10.5414/CP203578. PMID: 31933473.
Copy Download .nbib Format: NLM
Predictions for the COVID-19 pandemic in Germany using the modified Bateman SIZ model.

International journal of clinical pharmacology and therapeutics

Braun P, Haffner S, Aguirre Davila L, Braun J, Woodcock BG.
PMID: 32800093
Int J Clin Pharmacol Ther. 2020 Sep;58(9):467-474. doi: 10.5414/CP203868.

AIMS OF THE STUDY: To obtain predictions for the course of the COVID-19 pandemic in Germany using the modified Bateman SIZ model and input variables based on the status quo in July 2020. To predict the effect of a...

Cite
Braun P, Haffner S, Aguirre Davila L, et al. Predictions for the COVID-19 pandemic in Germany using the modified Bateman SIZ model. Int J Clin Pharmacol Ther. 2020;58(9):467-474doi: 10.5414/CP203868.
Braun, P., Haffner, S., Aguirre Davila, L., Braun, J., & Woodcock, B. G. (2020). Predictions for the COVID-19 pandemic in Germany using the modified Bateman SIZ model. International journal of clinical pharmacology and therapeutics, 58(9), 467-474. https://doi.org/10.5414/CP203868
Braun, Peter, et al. "Predictions for the COVID-19 pandemic in Germany using the modified Bateman SIZ model." International journal of clinical pharmacology and therapeutics vol. 58,9 (2020): 467-474. doi: https://doi.org/10.5414/CP203868
Braun P, Haffner S, Aguirre Davila L, Braun J, Woodcock BG. Predictions for the COVID-19 pandemic in Germany using the modified Bateman SIZ model. Int J Clin Pharmacol Ther. 2020 Sep;58(9):467-474. doi: 10.5414/CP203868. PMID: 32800093.
Copy Download .nbib Format: NLM
Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases.

International journal of clinical pharmacology and therapeutics

Ohyama K, Tanaka H, Shindo J, Shibayama M, Iwata M, Hori Y.
PMID: 34622771
Int J Clin Pharmacol Ther. 2021 Oct 08; doi: 10.5414/CP204066. Epub 2021 Oct 08.

OBJECTIVE: Gynecomastia is a benign proliferation of the glandular breast tissue in men and is generally caused by a decrease in androgen and an increase in estrogen. Diabetes has been reported to be a risk factor for lowering androgen...

Cite
Ohyama K, Tanaka H, Shindo J, et al. Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204066.
Ohyama, K., Tanaka, H., Shindo, J., Shibayama, M., Iwata, M., & Hori, Y. (2021). Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204066
Ohyama, Katsuhiro, et al. "Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204066
Ohyama K, Tanaka H, Shindo J, Shibayama M, Iwata M, Hori Y. Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases. Int J Clin Pharmacol Ther. 2021 Oct 08; doi: 10.5414/CP204066. Epub 2021 Oct 08. PMID: 34622771.
Copy Download .nbib Format: NLM
Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.

International journal of clinical pharmacology and therapeutics

Lee YH, Song GG.
PMID: 34889733
Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204108. Epub 2021 Dec 10.

OBJECTIVE: We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout.MATERIALS AND METHODS: A Bayesian network meta-analysis was performed to combine direct and indirect evidence from randomized controlled...

Cite
Lee YH, Song GG. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204108.
Lee, Y. H., & Song, G. G. (2021). Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204108
Lee, Young Ho, and Song, Gwan Gyu. "Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204108
Lee YH, Song GG. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021 Dec 10; doi: 10.5414/CP204108. Epub 2021 Dec 10. PMID: 34889733.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries